A Phase 3 interventional study of pemetrexed and cisplatin in Head and Neck Neoplasms, sponsored by Eli Lilly and Company. Completed at 94 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-28.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing pemetrexed in Head and Neck Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Pemetrexed · Head and Neck Neoplasms.
Among the 13 studies testing pemetrexed in Head and Neck Neoplasms, this one has the largest enrollment, is one of 6 that started in 2006, is the only one in phase 3, and was the 4th registered.
2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.
Browse Head and Neck Neoplasms studies →1 of the 13 studies testing pemetrexed in Head and Neck Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 795 is above the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 36 across the 13 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
14 studies in Head and Neck Neoplasms by Eli Lilly and Company: 1 open now, 3 under way, none of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 14 studies in Head and Neck Neoplasms by Eli Lilly and Company, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2006, is the only one in phase 3, and was the 1st registered.
Eli Lilly and Company’s Head and Neck Neoplasms studies by the year they started, since 2005.
1 of the studies testing pemetrexed in Head and Neck Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05358548Rutgers, The State University of New JerseyATATcH Alternating Treatment Plans for Advanced Cancer | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing pemetrexed in Head and Neck Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 14 in Head and Neck Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare the effects of pemetrexed plus cisplatin versus cisplatin alone in head and neck cancer patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pemetrexed 500 milligrams per meter square (mg/m\^2) administered intravenously (IV) plus cisplatin 75 mg/m\^2 IV on Day 1 every 21 days. Pretreatment, Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment. Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose. Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose.
Drug: pemetrexed · Drug: cisplatin
Placebo (approximately 100 mL normal saline) administered intravenously (IV) plus cisplatin 75 mg/m\^2 on Day 1 every 21 days. Pretreatment - Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment. Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose. Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose.
Drug: cisplatin · Drug: placebo
500 mg/m\^2, IV, every 21 days, six 21 day cycles
Also known as: Alimta, LY231514
75 mg/m\^2, administered IV, every 21 days, six 21 day cycles
Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
Overall Survival (OS)
OS duration is defined as the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cut-off date, OS duration will be censored at the date of the participant's last contact prior to that cut-off date.
Time frame: Baseline to date of death from any cause up to 36 months
Progression-free Survival (PFS)
Objective PFS is defined as the time from date of randomization to date of objectively determined progressive disease (PD) or death from any cause, whichever comes first. PD was defined by Response Evaluation Criteria in Solid Tumors (RECIST). PD=at least a 20% increase in sum of longest diameter of target lesions. For participants who are not known to have died as of the data-inclusion cut-off date, and who do not have progressive disease, PFS will be censored at the date of the last objective progression-free disease assessment prior to the date of any subsequent systemic anticancer therapy.
Time frame: baseline to measured progressive disease up to 33 months
Percent of Participants With a Tumor Response (Response Rate)
Tumor Response is evaluated as CR (Complete Response) or PR (Partial Response) per Response Evaluation Criteria in Solid Tumors (RECIST criteria). Possible evaluations include: CR: Disappearance of all target lesions. PR: At least a 30% decrease in the size of target lesions. Response rate (%) = (number of participants with CR+PR/number of participants)\*100
Time frame: Baseline to progressive disease or discontinuation of study treatment up to 11 months
Duration of Response (DoR)
DoR is time from first observation of complete response (CR) or partial response (PR) to first observation of PD or death. Response is objective status of CR or PR using RECIST criteria. CR is disappearance of lesions. PR is \>30% decrease in size of lesions. Responder is any participant with CR or PR. PD is at least 20% increase in sum of longest diameter of target lesions. For participants alive as of data-inclusion cut-off date and who do not have PD, DoR will be censored at date of last objective progression-free disease assessment before date of any subsequent systemic anticancer therapy.
Time frame: time of response to progressive disease up to 24 months
Time to Treatment Worsening in Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Total Score
FACT-H\&N consists of 39 items with 5-point rating scale from 0 (not at all) to 4 (very much). FACT-H\&N Total score ranges from 0 to 148. Higher score represents a better quality of life. Time to worsening was defined as the first date of worsening in the FACT H\&N Total score that was considered at least the prospectively defined minimally important difference (MID) as compared with participant's baseline score, or date of death from any cause. The MID for FACT H\&N Total score was a decrease of 12 points.
Time frame: Baseline (</=Day 1 of first dose) and Day 1 of every subsequent cycle to 30-day post-study completion up to 33 months
Correlation Between Biomarkers and Treatment Effect
Correlation between highly up/downregulated genes and clinical response (Overall Survival (OS) and Progression-Free Survival (PFS)). OS is is defined as the time from the date of randomization to the date of death from any cause. PFS is defined as the time from the date of randomization to the date of objectively determined progressive disease or death from any cause, whichever comes first. 0 participants were analyzed; Reason: The relatively low number of samples collected would not have yielded a meaningful genomic analysis and the decision was made to not analyze the data.
Time frame: Baseline
| Milestone | Pemetrexed/Cisplatin | Placebo/Cisplatin |
|---|---|---|
| Started | 398 | 397 |
| Received at least 1 dose of study drug | 392 | 385 |
| Completed | 70 | 55 |
| Not completed | 328 | 342 |
| Withdrew: Adverse event | 37 | 32 |
| Withdrew: Entry criteria not met | 4 | 8 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 10 | 16 |
| Withdrew: Progressive disease | 180 | 217 |
| Withdrew: Protocol violation | 4 | 2 |
| Withdrew: Withdrawal by subject | 28 | 21 |
| Withdrew: Death due to study disease | 26 | 29 |
| Withdrew: Death due to study drug related ae | 11 | 1 |
| Withdrew: Death due to procedural related ae | 0 | 1 |
| Withdrew: Death due to ae (other causes) | 27 | 15 |
OS duration is defined as the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cut-off date, OS duration will be censored at the date of the participant's last contact prior to that cut-off date.
| Months | Pemetrexed/Cisplatin | Placebo/Cisplatin |
|---|---|---|
| Overall Survival (OS) | 7.33 (6.34 to 8.38) | 6.28 (5.52 to 7.06) |
Objective PFS is defined as the time from date of randomization to date of objectively determined progressive disease (PD) or death from any cause, whichever comes first. PD was defined by Response Evaluation Criteria in Solid Tumors (RECIST). PD=at least a 20% increase in sum of longest diameter of target lesions. For participants who are not known to have died as of the data-inclusion cut-off date, and who do not have progressive disease, PFS will be censored at the date of the last objective progression-free disease assessment prior to the date of any subsequent systemic anticancer therapy.
| months | Pemetrexed/Cisplatin | Placebo/Cisplatin |
|---|---|---|
| Progression-free Survival (PFS) | 3.61 (3.15 to 4.07) | 2.79 (2.69 to 3.22) |
Tumor Response is evaluated as CR (Complete Response) or PR (Partial Response) per Response Evaluation Criteria in Solid Tumors (RECIST criteria). Possible evaluations include: CR: Disappearance of all target lesions. PR: At least a 30% decrease in the size of target lesions. Response rate (%) = (number of participants with CR+PR/number of participants)\*100
| Percentage of participants | Pemetrexed/Cisplatin | Placebo/Cisplatin |
|---|---|---|
| Percent of Participants With a Tumor Response (Response Rate) | 12.1 | 8.1 |
DoR is time from first observation of complete response (CR) or partial response (PR) to first observation of PD or death. Response is objective status of CR or PR using RECIST criteria. CR is disappearance of lesions. PR is \>30% decrease in size of lesions. Responder is any participant with CR or PR. PD is at least 20% increase in sum of longest diameter of target lesions. For participants alive as of data-inclusion cut-off date and who do not have PD, DoR will be censored at date of last objective progression-free disease assessment before date of any subsequent systemic anticancer therapy.
| Months | Pemetrexed/Cisplatin | Placebo/Cisplatin |
|---|---|---|
| Duration of Response (DoR) | 5.29 (4.21 to 5.98) | 4.37 (3.58 to 6.44) |
FACT-H\&N consists of 39 items with 5-point rating scale from 0 (not at all) to 4 (very much). FACT-H\&N Total score ranges from 0 to 148. Higher score represents a better quality of life. Time to worsening was defined as the first date of worsening in the FACT H\&N Total score that was considered at least the prospectively defined minimally important difference (MID) as compared with participant's baseline score, or date of death from any cause. The MID for FACT H\&N Total score was a decrease of 12 points.
| Months | Pemetrexed/Cisplatin | Placebo/Cisplatin |
|---|---|---|
| Time to Treatment Worsening in Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Total Score | 3.29 (2.76 to 4.11) | 2.89 (2.40 to 3.19) |
Correlation between highly up/downregulated genes and clinical response (Overall Survival (OS) and Progression-Free Survival (PFS)). OS is is defined as the time from the date of randomization to the date of death from any cause. PFS is defined as the time from the date of randomization to the date of objectively determined progressive disease or death from any cause, whichever comes first. 0 participants were analyzed; Reason: The relatively low number of samples collected would not have yielded a meaningful genomic analysis and the decision was made to not analyze the data.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed/Cisplatin | — | 185/392 (47.2%) | 343/392 (87.5%) |
| Placebo/Cisplatin | — | 132/385 (34.3%) | 316/385 (82.1%) |
| Event | Pemetrexed/Cisplatin | Placebo/Cisplatin |
|---|---|---|
| PneumoniaInfections and infestations | 26/392 | 7/385 |
| AnaemiaBlood and lymphatic system disorders | 22/392 | 17/385 |
| VomitingGastrointestinal disorders | 22/392 | 9/385 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 10/392 | 15/385 |
| LeukopeniaBlood and lymphatic system disorders | 14/392 | 1/385 |
| DiarrhoeaGastrointestinal disorders | 14/392 | 1/385 |
| NauseaGastrointestinal disorders | 13/392 | 7/385 |
| Febrile neutropeniaBlood and lymphatic system disorders | 12/392 | 0/385 |
| NeutropeniaBlood and lymphatic system disorders | 12/392 | 3/385 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/392 | 3/385 |
| Event | Pemetrexed/Cisplatin | Placebo/Cisplatin |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 118/392 | 79/385 |
| NauseaGastrointestinal disorders | 118/392 | 106/385 |
| VomitingGastrointestinal disorders | 62/392 | 79/385 |
| NeutropeniaBlood and lymphatic system disorders | 67/392 | 35/385 |
| FatigueGeneral disorders | 67/392 | 53/385 |
| ConstipationGastrointestinal disorders | 56/392 | 53/385 |
| AnorexiaMetabolism and nutrition disorders | 52/392 | 44/385 |
| Weight decreasedInvestigations | 45/392 | 50/385 |
| DiarrhoeaGastrointestinal disorders | 42/392 | 33/385 |
| PyrexiaGeneral disorders | 40/392 | 19/385 |
| Age Continuous(years) | Pemetrexed/Cisplatin | Placebo/Cisplatin | Total |
|---|---|---|---|
| Mean | 57.45 ± 9.54 | 57.78 ± 9.36 | 57.62 ± 9.44 |
| Sex: Female, Male(Participants) | Pemetrexed/Cisplatin | Placebo/Cisplatin | Total |
|---|---|---|---|
| Female | 56 | 53 | 109 |
| Male | 342 | 344 | 686 |
| Race/Ethnicity, Customized(Participants) | Pemetrexed/Cisplatin | Placebo/Cisplatin | Total |
|---|---|---|---|
| African | 17 | 12 | 29 |
| Caucasian | 243 | 233 | 476 |
| East Asian | 55 | 65 | 120 |
| Hispanic | 11 | 16 | 27 |
| West Asian (Indian sub-continent) | 72 | 70 | 142 |
| Unknown | 0 | 1 | 1 |
| Region of Enrollment(participants) | Pemetrexed/Cisplatin | Placebo/Cisplatin | Total |
|---|---|---|---|
| Argentina | 5 | 10 | 15 |
| Belgium | 7 | 10 | 17 |
| Brazil | 16 | 12 | 28 |
| China | 5 | 7 | 12 |
| Denmark | 7 | 3 | 10 |
| France | 3 | 3 | 6 |
| Germany | 50 | 48 | 98 |
| Hungary | 23 | 22 | 45 |
| India | 72 | 75 | 147 |
| Italy | 19 | 21 | 40 |
| Korea, Republic of | 29 | 24 | 53 |
| Mexico | 9 | 8 | 17 |
| Netherlands | 8 | 11 | 19 |
| Poland | 10 | 10 | 20 |
| Romania | 20 | 22 | 42 |
| Russian Federation | 23 | 20 | 43 |
| South Africa | 11 | 9 | 20 |
| Spain | 31 | 29 | 60 |
| Taiwan | 21 | 25 | 46 |
| United States | 29 | 28 | 57 |
| Previously Treated for Head and Neck Cancer (HNC)(Participants) | Pemetrexed/Cisplatin | Placebo/Cisplatin | Total |
|---|---|---|---|
| No | 35 | 39 | 74 |
| Yes | 363 | 358 | 721 |
| Prior Treatment with Platinum-Based Therapy(Participants) | Pemetrexed/Cisplatin | Placebo/Cisplatin | Total |
|---|---|---|---|
| No | 213 | 228 | 441 |
| Yes | 185 | 169 | 354 |
| Distant Metastasis(Participants) | Pemetrexed/Cisplatin | Placebo/Cisplatin | Total |
|---|---|---|---|
| No | 165 | 155 | 320 |
| Yes | 233 | 242 | 475 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Pemetrexed/Cisplatin | Placebo/Cisplatin | Total |
|---|---|---|---|
| 0 | 90 | 90 | 180 |
| 1 | 257 | 253 | 510 |
| 2 | 51 | 53 | 104 |
| Missing Data | 0 | 1 | 1 |
1 further baseline measures are reported on the registry.
The record gives a start of Dec 2006, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed